[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vascular-access-complication\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vascular-access-complication":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,47,78,115,147,188,219,242,265,298,331,355],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100641241","impact-of-a-tunneled-hemodialysis-catheter-with-endexo-technology-on-catheter-dysfunction-compared-with-historical-catheter-dysfunction-data-in-standard-catheters-100641241",false,"NCT07655544","Impact of a Tunneled Hemodialysis Catheter With Endexo® Technology on Catheter Dysfunction Compared With Historical Catheter Dysfunction Data in Standard Catheters","Impact of a Tunneled Hemodialysis Catheter With Endexo® Technology on Catheter Dysfunction Compared With Historical Catheter Dysfunction Data in Standard Catheters (Silicone or Polyurethane): A Pilot Study","Inclusion Criteria:\n\n* Adult patients aged greater than 18 years\n* Written informed consent\n* Requirement for hemodialysis using a tunneled dialysis catheter\n\nExclusion Criteria:\n\n* Children aged less than 18 years\n* Uncontrolled infection; defined as positive blood culture in the past seven days before catheter insertion and\u002F or elevated C-reactive protein \\[CRP \\>5 mg\u002Fdl (normal \\\u003C0.5 mg\u002Fdl)\\] at screening","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"NA","There is evidence that central venous catheters made of the permanent and non-eluting integral polymer Endexo® are more resistant to intraluminal thrombosis. This has a direct reducing effect on catheter malfunctions. Indirectly, due to reduced handling of the dysfunctional catheter, this may lead to a diminished rate of catheter related infections. Since catheter malfunctions and infections represent leading complications in a dialysis population, dialysis catheters produced with Endexo® technology have the potential to have beneficial clinical effects. In addition to improving patient outcomes, this could also reduce overall costs. In this pilot study the tunneled hemodialysis catheter BioFlo Duramax with Endexo® technology (Merit Medical, Utah, USA) will be compared with historical catheter dysfunction rates in standard tunneled dialysis catheters (silicone or polyurethane) in chronic dialysis population.",[26,27,28,29,30,31,32,33],"Haemodialysis","Haemodialysis Complication","Vascular Access","Vascular Access Complication","ESRD (End Stage Renal Disease)","Dialysis Access Dysfunction","Dialysis Catheter","Dialysis Catheter Infections","NOT_YET_RECRUITING","2026-06-11",{"date":37,"type":38},"2026-06-18","ACTUAL",{"date":40,"type":20},"2026-08-01",{"date":42,"type":20},"2027-12-31",{"name":44,"class":45},"Medical University of Vienna","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100640666","the-ivcare-adaptive-platform-trial-100640666","NCT07587593","The IVCare Adaptive Platform Trial","Comparative Effectiveness of Interventions to Prevent Infections and Other Complications Arising From Central Venous Access Devices: the IVCare Adaptive Platform Trial.","Core inclusion Criteria:\n\n* The patient has or requires a CVAD, including a PICC, a non-tunnelled or tunnelled CVC, or a totally implanted venous access port.\n* Patient is less than 18 years old and paediatric recruitment has not been approved at the site.\n\nSecurement Domain exclusion criteria:\n\n* Central line-associated bloodstream infection (CLABSI) currently suspected associated with any vascular access device (peripheral or central) that is in situ.\n* CLABSI diagnosed from any vascular access device currently in situ within the past 7 days or being actively treated with antimicrobials.\n* Participants with an estimated life expectancy of \\\u003C30 days OR who have commenced a documented end-of-life, terminal-care, or comfort-care pathway.\n* Participants who have previously been randomised for the same CVAD.\n* Participants who have been randomised three times.\n* SecurAcath® cannot be applied in accordance with manufacturer instructions and local policy.\n* The participant has compromised skin integrity at the current or intended insertion site, including active infection, inflammation, erosion, ulceration, or pre-existing exit-site injury.\n\nConnectors\u002FCaps Domain exclusion criteria:\n\n* Central line-associated bloodstream infection (CLABSI) currently suspected associated with any vascular access device (peripheral or central) that is in situ.\n* CLABSI diagnosed within the past 14 days or CLABSI being actively treated with antimicrobials, associated with any vascular access device currently in situ.\n* Participants with an estimated life expectancy of \\\u003C30 days OR who have commenced a documented end-of-life, terminal-care, or comfort-care pathway.\n* Participants who have previously been randomised for the same CVAD.\n* Participants who have been randomised three times.\n* Known or suspected hypersensitivity or a confirmed allergy to chlorhexidine or silver-containing products.\n\nCancer stratum inclusion criteria:\n\n* Confirmed diagnosis of a solid tumour OR\n* Confirmed diagnosis of a haematological malignancy. OR\n* Bone marrow failure syndrome requiring systemic therapy, immunosuppression, or haematopoietic stem cell transplantation.\n\nKidney stratum exclusion criteria:\n\n• Confirmed diagnosis of kidney disease.",{"count":55,"type":20},2500,[23],"The IVCare trial is a multicentre adaptive platform study evaluating interventions to prevent infections and other complications associated with central venous access devices (CVADs) in patients with newly inserted or existing devices. The study is organised into domains addressing different aspects of CVAD care and includes patient groups referred to as strata. Domains, strata and interventions may change over time as the study progresses. IVCare also includes an observational cohort study in which patients with CVADs are followed to assess CVAD care practices, infections, and other CVAD-related complications across health services.\n\nThe trial starts with two domains. The Connectors\u002FCaps Domain compares antimicrobial chlorhexidine-containing connectors and caps with standard-of-care connectors and caps used in Australian hospitals. In the cancer stratum, participants are randomised to receive either InVision-Plus CS® or standard-of-care connectors\u002Fcaps. In the kidney disease stratum, participants are randomised to receive either ClearGuard™ HD or standard-of-care connectors\u002Fcaps. Following a predefined stopping decision for ClearGuard™ HD in the kidney disease stratum, Tego™ will be introduced and evaluated in this group.\n\nThe Securement Domain compares the effectiveness of SecurAcath®, a subcutaneous anchor securement system, with standard-of-care securement methods used in Australian hospitals. Participants in both the cancer and kidney disease strata are randomised to receive either SecurAcath® or standard-of-care securement.",[59,29,60,61],"Device Related Infection","Device Related Sepsis","Catheter Infection",[63,64,65,66,67,68],"Central venous access device","Chlorhexidine cap","Chlorhexidine connector","Subcutaneous anchor","Central line-associated blood stream infection","Adaptive platform trial","2026-05-07",{"date":71,"type":38},"2026-05-14",{"date":73,"type":20},"2026-12-01",{"date":75,"type":20},"2031-12-01",{"name":77,"class":45},"The University of Queensland",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":88,"briefSummary":89,"conditions":90,"keywords":97,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":46},"100594451","chlorhexidine-caps-for-clabsi-prevention-in-hemodialysis-a-pilot-randomized-controlled-trial-100594451","NCT07019610","Chlorhexidine Caps for CLABSI Prevention in Hemodialysis: a Pilot Randomized Controlled Trial","Evaluation of Chlorhexidine Caps for Central Line Associated Blood Stream Infection Prevention in People Needing Hemodialysis: a Pilot Randomised Control Trial","ECHO-HD","Inclusion Criteria:\n\n* Age≥18\n* Able to provide informed consent\n* Kidney failure requiring a tunnelled CVC for treatment (haemodialysis)\n* 21 days BSI free\n* No known allergy to chlorhexidine and\u002For nylon and\u002For polypropylene.\n\nExclusion Criteria:\n\n* Current CLABSI\n* Known allergic to chlorhexidine and\u002For nylon and\u002For polypropylene.\n* Patients on an end-of-life pathway\n* People with a cognitive impairment and\u002For intellectual disability",{"count":87,"type":20},60,[23],"The goal of this clinical trial is to compare a chlorhexidine antimicrobial barrier cap in patients requiring hemodialysis treatment to the standard hemodialysis caps currently used within the Metro North Kidney Health Service.\n\nThe main questions to answer are:\n\n* Study Feasibility\n* Occurrence of infectious complications related to renal central venous catheters\n\nParticipants will be randomly allocated to receive either of the below hemodialysis caps to cover their hemodialysis catheter hub:\n\n* The standard hemodialysis cap used at the Royal Brisbane and Women's Hospital, or\n* The intervention hemodialysis cap containing chlorhexidine inside it\n\nResearchers will compare standard and chlorhexidine hemodialysis caps to see if the presence of chlorhexidine improves the occurrance of infectious complications related to the hemodialysis catheter.",[29,59,60,61,91,92,93,94,95,96],"Catheter Complications","Catheter-Related Infections","Catheter Related Complications","Hemodialysis Catheter Infection","Hemodialysis Catheter-associated Infection","Hemodialysis Complication",[98,99,100,101,102,64,103,104,105,106],"Hemodialysis Catheter","Randomised Controlled Trial","Antimicrobial Barrier Caps","Vascular access device","Hemodialysis catheter caps","Central Venous Catheter","CVC","CLABSI","Central Line Associated Blood Stream Infection","2026-04-27",{"date":109,"type":38},"2026-04-29",{"date":111,"type":20},"2026-06",{"date":113,"type":20},"2028-02",{"name":77,"class":45},{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":21,"phases":125,"briefSummary":126,"conditions":127,"keywords":131,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":146},"100575291","effectiveness-of-a-zinc-oxide-adhesive-securement-device-in-the-fixation-of-midline-and-peripherally-inserted-central-catheters-in-hospitalized-adult-patients-100575291","NCT06770374","Effectiveness of a Zinc Oxide Adhesive Securement Device in the Fixation of Midline and Peripherally Inserted Central Catheters in Hospitalized Adult Patients","Effectiveness of a Zinc Oxide Adhesive Securement Device in the Fixation of Midline and Peripherally Inserted Central Catheters in Hospitalized Adult Patients: Randomised Clinical Trial","FIX-ETI","Inclusion Criteria:\n\n* requiring cannulation of a midline catheter or a PICC\n* who accepted and signed the informed consent voluntarily\n* with an inpatient unit admission of minimum 7 days\n\nExclusion Criteria:\n\n\\- patients with a known allergy to zinc oxide",{"count":124,"type":20},400,[23],"Study in which a zinc oxide fixation device (a product that can help protect the skin) for catheters (polyurethane tubes inserted into a vein) will be tested to reduce catheter-related complications: catheter displacement, skin complications, phlebitis and pain..",[29,128,129,130],"Skin and Subcutaneous Tissue Disorders","Phlebitis","Pain",[132,133,92,134,135,99],"Catheters","Vascular Access Devices","Nurse Specialists","Nurses","RECRUITING","2026-04-02",{"date":139,"type":38},"2026-04-08",{"date":141,"type":38},"2025-02-01",{"date":143,"type":20},"2026-12-31",{"name":145,"class":45},"Hospital Arnau de Vilanova",2,{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":21,"phases":156,"briefSummary":157,"conditions":158,"keywords":167,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":187},"100516231","save-fistulas-the-selfwrap-assisted-arteriovenous-fistulas-study-100516231","NCT06001827","SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study","SAVE-FistulaS","Inclusion Criteria:\n\n* Age of at least 18 years\n* Referred for creation of a new AVF\n* Willing and able to comply with study requirements, communicate with the study team, and attend follow up visits over a period of 36 months\n\nExclusion Criteria:\n\n* Planned index procedure to revise or repair an existing fistula\n* Target artery inner diameter \\\u003C 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia\n* Target vein inner diameter \\\u003C 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia\n* Significant (at least 50%) stenosis at the target vein on the side of surgery (between the planned anastomosis site and the axillary vein), as diagnosed by preoperative ultrasound\n* Known central venous stenosis of at least 50% on the side of surgery\n* Presence of a stent or a stent graft within the access circuit\n* Known or suspected coagulation disorder that, in the opinion of the Investigator, puts too much risk on the patient for AVF creation\n* Known or suspected active infection at the time of surgery\n* Congestive heart failure NYHA class 4\n* Prior steal on the side of surgery;\n* Enrolled in another investigational drug, device, or biological study, or was previously enrolled in this study\n* Life expectancy less than 12 months\n* Expected to undergo kidney transplant surgery within 6 months of enrollment\n* Expected to undergo home hemodialysis\n* Females of childbearing potential (premenopausal and not surgically sterile) without documented current negative pregnancy test at screening\n* Presence of a comorbid condition that, in the opinion of the Investigator, may significantly confound the collection of safety and efficacy data in this study\n* Unwillingness or inability to give consent and\u002For comply with the study follow up schedule\n* Any health condition, which in the opinion of the Investigator, would interfere with the safety of the participant or the participant's ability to comply with the study.",{"count":155,"type":20},600,[23],"This is a prospective, randomized, multi-center clinical trial for chronic kidney disease (CKD) patients referred for creation of a new arteriovenous fistula (AVF) in order to assess the safety and effectiveness of SelfWrap, a bioabsorbable perivascular wrap.",[159,160,161,162,163,29,164,91,165,166],"Chronic Kidney Diseases","End Stage Renal Disease","Arteriovenous Fistula","Hemodialysis Access Failure","ESRD","Renal Failure","Catheter Dysfunction","Renal Insufficiency",[168,28,169,170,171,172,173,174,175,160,161,176],"Vascular Surgery","Nephrology","Bioabsorbable","Perivascular Wrap","External Support","Hemodialysis","Dialysis","Chronic Kidney Disease","AVF","2026-02-12",{"date":179,"type":38},"2026-02-17",{"date":181,"type":38},"2024-01-03",{"date":183,"type":20},"2029-12",{"name":185,"class":186},"VenoStent","INDUSTRY",28,{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":21,"phases":199,"briefSummary":200,"conditions":201,"keywords":205,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":46},"100606744","time-to-ambulation-after-proglide-closure-100606744","NCT07179536","Time to Ambulation After ProGlide Closure","Optimizing Time to Ambulation After ProGlide Closure of Femoral Access: A Randomized Controlled Trial","OPTIMA","Inclusion Criteria:\n\n* Scheduled for peripheral angiography or endovascular intervention via transfemoral access.\n* Femoral artery puncture site located at the common femoral artery.\n* Use of 6-8F vascular sheath.\n* Hemostasis achieved with 6F ProGlide closure device (defined as no active bleeding, no hematoma formation, and no ischemia of the punctured limb after closure).\n* Preoperative ankle-brachial index (ABI) \\> 0.9 on both sides.\n* Conscious, cooperative, and with normal lower limb mobility.\n\nExclusion Criteria:\n\n* Undergoing carotid artery intervention.\n* Femoral artery diameter \\\u003C 5 mm, or effective lumen \\\u003C 5 mm due to plaque burden.\n* History of vascular complications at the puncture site.\n* Abnormal cardiopulmonary function.\n* Intraoperative platelet count \\\u003C 80 × 10⁹\u002FL, or use of thrombolytic agents.\n* Cognitive impairment, uncooperative, or limited lower limb mobility.","75 Years",{"count":198,"type":20},300,[23],"Transradial access has become the standard for coronary procedures due to fewer vascular complications and shorter bed rest, yet transfemoral access remains essential for complex peripheral interventions requiring larger sheaths and stronger support. Vascular closure devices (VCDs), particularly suture-mediated devices such as ProGlide, have improved femoral access by reducing hemostasis time, ambulation delay, and patient discomfort. Although early ambulation after ProGlide closure has been reported, current practice varies widely, and the relationship between ambulation timing and vascular complications remains unclear. This trial aims to evaluate the effect of different ambulation times after ProGlide closure in transfemoral peripheral angiography or intervention, with the goal of identifying the optimal time to ambulation that balances safety and efficiency.",[202,203,29,204],"Femoral Access Site Closure","Ambulation","Vascular Access Site Management",[206,207,208,209],"Femoral access site closure","Vascular closure device","Time to ambulation","Vascular access complication","2026-01-21",{"date":212,"type":38},"2026-01-23",{"date":214,"type":38},"2025-10-01",{"date":216,"type":20},"2026-03-30",{"name":218,"class":45},"Chinese Academy of Medical Sciences, Fuwai Hospital",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":226,"enrollmentInfo":227,"targetDuration":4,"studyType":21,"phases":229,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":240,"locationsCount":46},"100621546","single-needle-distal-return-for-long-term-arteriovenous-fistula-care-100621546","NCT07372027","Single-Needle Distal Return for Long-Term Arteriovenous Fistula Care","A Prospective Study on the Efficacy and Cost-Effectiveness of Modified Single-Needle Distal Return Cannulation for Long-Term Arteriovenous Fistula Care in Maintenance Hemodialysis Patients","Inclusion Criteria:\n\n* Adult patients (age ≥ 18 years).\n\nDiagnosis of end-stage kidney disease (ESKD) requiring maintenance hemodialysis (three times per week).\n\nReliable use of a native arteriovenous fistula (AVF) as the primary vascular access for at least the past 3 months.\n\nWilling and able to provide written informed consent to participate in the study.\n\nAdequate superficial venous vasculature in at least one lower extremity (e.g., dorsal foot veins, saphenous tributaries) as assessed by clinical evaluation and\u002For bedside ultrasound, deemed suitable for cannulation as a venous return site.\n\nFor the experimental (SNDR) group: Expressed willingness to adopt the single-needle distal return cannulation strategy.\n\nFor the control group: Currently receiving and willing to continue standard two-needle AVF cannulation.\n\nExclusion Criteria:\n\n* Active systemic infection or localized infection at the potential cannulation sites (AVF or lower extremity veins).\n\nKnown severe coagulation disorder or thrombocytopenia (platelet count \\\u003C 50 × 10⁹\u002FL) that would pose a high risk of bleeding complications from cannulation.\n\nSevere peripheral arterial disease or venous insufficiency in the lower extremities that contraindicates venous cannulation or may compromise limb perfusion.\n\nUnstable cardiovascular status (e.g., uncontrolled heart failure, severe arrhythmias) as determined by the treating nephrologist, which would increase the risk associated with any change in dialysis procedure.\n\nDocumented severe cognitive impairment, psychiatric illness, or any condition that would impair the ability to provide informed consent or adhere to the study protocol.\n\nLife expectancy less than 12 months due to non-renal comorbid conditions (e.g., metastatic malignancy).\n\nCurrently pregnant or breastfeeding.\n\nParticipation in another interventional clinical trial that could confound the outcomes of this study.\n\nAnatomical or pathological condition of the AVF (e.g., extreme depth, aneurysm with overlying skin compromise, complete thrombosis) that precludes safe single-needle cannulation, as judged by the study vascular access team.\n\nInability to comply with the scheduled study visits and follow-up assessments.","100 Years",{"count":228,"type":20},100,[23],"Background:\n\nFor millions of people worldwide with kidney failure, a well-functioning vascular access, like an arteriovenous fistula (AVF), is essential for life-sustaining hemodialysis. However, the standard method requires puncturing the same AVF with two needles three times a week, which over time can damage the vessel, leading to scarring, narrowing, and frequent failures. These complications often require repeated surgical or minimally invasive procedures (reinterventions), causing significant pain, high medical costs, and exhaustion of the patient's limited blood vessels.\n\nNew Approach:\n\nThis study will evaluate a modified puncture technique called the Single-Needle Distal Return (SNDR) strategy for long-term AVF care. Instead of using two needles in the AVF, only one needle is placed in the AVF to draw blood. The cleaned blood is then returned to the body through a second needle placed in a superficial vein in the foot or lower leg. This approach aims to reduce trauma to the critical AVF.\n\nStudy Plan:\n\nThis is a clinical study conducted at the Blood Purification Center of Anhui Medical University Affiliated Suzhou Hospital. We plan to enroll approximately 50 adult hemodialysis patients who use an AVF and are willing to try the SNDR technique. For comparison, we will also observe data from a similar number of patients receiving standard two-needle AVF care during the same period.\n\nThe study will last about three years. We will closely monitor patients using the SNDR technique to assess:\n\nEffectiveness: Whether dialysis remains adequate (measured by Kt\u002FV).\n\nSafety: Rates of complications (like bruising or infection), dialysis machine alarms, and venous pressure during treatment.\n\nPractical Benefits: Whether it reduces the need for repair procedures (reinterventions) and hospitalizations related to the AVF.\n\nEconomic Impact: Changes in healthcare costs.\n\nPatient Experience: Patient tolerance and comfort with the technique. We will also analyze the characteristics of patients who successfully use this technique long-term to help identify who might benefit most from it in the future.\n\nPotential Significance:\n\nIf proven successful and safe for long-term use, the SNDR strategy could help protect a patient's precious AVF, potentially reducing painful procedures, lowering costs, slowing down the exhaustion of blood vessels, and improving the quality of life for people on long-term dialysis. The findings may also guide better planning for vascular access care.",[232,161,233,28,29],"Hemodialysis Access","Arteriovenous Fistula Cannulation","2026-01-19",{"date":236,"type":38},"2026-01-28",{"date":238,"type":20},"2026-12-15",{"date":143,"type":20},{"name":241,"class":45},"Suzhou Municipal Hospital of Anhui Province",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":21,"phases":251,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":264},"100476920","access-cannulation-trial-ii-100476920","NCT05490225","Access Cannulation Trial II","A Study to Evaluate the Safety and Effectiveness of Voyager's Access Device for Patients Undergoing Routine Hemodialysis (Access Cannulation Trial II)","ACT II","Inclusion:\n\n1. The subject's AVF is deemed uncannulatable because:\n\n   1. The subject's anticipated cannulation zone(s) is\u002Fare \\>6mm in depth from the surface of the skin to the anterior wall of the access vein as confirmed by ultrasound within 8 weeks prior to device implantation (each zone, Arterial\u002FPull and Venous\u002FPush, shall be assessed independently of one another for device placement):\n\n      * Arterial\u002FPull Zone: \\_\\_\\_\\_\\_ mm deep\n      * Venous\u002FPush Zone: \\_\\_\\_\\_\\_ mm deep\n\n      OR\n   2. The subject's dialysis unit (which includes an experienced cannulator) attests that repeated cannulation is not achievable in their clinic due to one of the following:\n\n      * Failed access attempt in a fistula that was previously approved for cannulation, or\n      * Unable to palpate the fistula such that cannulation is not possible without patient risk.\n2. The access surgeon caring for the subject attests that the device is likely to be at least equivalent to other methods (such as venous transposition or suction-assisted lipectomy) that could make the AVF easier to access and reduce risk of cannulation infiltrations.\n3. The subject has either a radio-cephalic, brachio-cephalic or transposed brachio-basilic fistula.\n\nExclusion:\n\n1. The subject's access vein is \\>15mm in depth at either cannulation zones as measured by ultrasound within 8 weeks prior to device implantation.\n\n   * Arterial\u002FPull Zone: \\_\\_\\_\\_\\_ mm in depth\n   * Venous\u002FPush Zone: \\_\\_\\_\\_\\_ mm in depth Note: these values should match inclusion criteria #1\n2. Both bidimensional measurements in the subject's access vein have a diameter of \\\u003C4mm, taken with a tourniquet in place or through manual compression to the outflow, as measured by ultrasound within 8 weeks prior to device implantation (cannulation zone specific - one zone does not affect the other's eligibility).\n\n   * Arterial\u002FPull Zone: \\_\\_\\_\\_\\_ x \\_\\_\\_\\_\\_ mm in diameter\n   * Venous\u002FPush Zone: \\_\\_\\_\\_\\_ x \\_\\_\\_\\_\\_ mm in diameter\n3. The subject has a flow rate of \\\u003C550mL\u002Fmin in the inflow artery proximal to the arterial anastomosis as measured by ultrasound within 8 weeks prior to device implantation.\n\n   • Flow: \\_\\_\\_\\_\\_ mL\u002Fmin\n4. The subject does NOT have a prescription to receive maintenance hemodialysis at least 2 times per week.\n5. The subject's life expectancy is \\\u003C1 year per the Investigator.\n6. The subject does NOT have a signed and dated consent form.\n7. The AVF is a non-transposed basilic or brachial vein outflow AVF.\n8. The subject has high flow rates placing them at risk for heart failure and death at the discretion of the Investigator.\n9. The subject has a known skin infection, hypersensitive skin, skin breakdown\u002Ferosion or skin allergies at the potential implant sites.\n10. The subject has a known active systemic infection or positive blood cultures present.\n11. The subject's AVF has undergone a major revision and at the discretion of the Investigator can impact fistula viability and device placement (such as DRIL or PTFE segment insertion, banding, aneurysm repair, etc.), or the subject has had an occurrence of and\u002For intervention for AV access stenosis or thrombosis within the past month (excluded to avoid unnecessary placement into an AVF with a high likelihood of failure).\n12. The subject is \\\u003C18 years of age.\n13. The subject plans to become pregnant prior to their potential treatment date.\n14. The subject has a body mass index \\>50kg\u002Fm2.\n15. The subject has a known clinically significant bleeding or coagulation disorder, including but not limited to low platelet count (\\\u003C50,000), hypercoagulable state (e.g., antithrombin IE deficiency, antiphospholipid or anticardiolipin antibodies, Factor V Leiden, circulating Lupus anticoagulant, current, heparin-induced thrombocytopenia, protein C or S deficiency, history of recurrent deep vein thrombosis not related to AV access).\n16. The subject has an active malignancy.\n17. The subject has a known or suspected allergy to titanium, aluminum, or vanadium.\n18. The subject has had a significant cardiovascular event\u002Fintervention that makes them a poor surgical candidate such as myocardial infarction, angioplasty, or stent placement within 3 months of implantation.\n19. The subject has had a significant peripheral vascular disease requiring a major intervention within the previous 12 months (in the target limb).\n20. The subject has had a significant neurovascular event such as stroke or major intervention within the previous 12 months.\n21. The subject has an uncontrolled major symptomatic medical problem per the Investigator.\n22. The subject has a likelihood of poor protocol compliance due to mental incapacity, an inability to understand treatment instructions, or for any other reason in the opinion of the Investigator.\n23. The subject is currently participating in another investigational drug or device investigation that could clinically interfere with the endpoints of this investigation.\n24. The subject's conversion to home hemodialysis is anticipated at any point during their foreseeable participation in this investigation.",{"count":228,"type":20},[23],"This is a pivotal, interventional, prospective, single-arm, open-label, multi-site clinical investigation intended to support FDA clearance of the study device based on the safety and efficacy of the device in cannulating arteriovenous fistulas (AVFs) for hemodialysis procedures.",[254,29],"Dialysis; Complications","2025-10-27",{"date":257,"type":38},"2025-10-29",{"date":259,"type":38},"2025-04-23",{"date":261,"type":20},"2027-03-25",{"name":263,"class":186},"Voyager Biomedical",8,{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":21,"phases":275,"briefSummary":276,"conditions":277,"keywords":283,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":295,"leadSponsor":296,"locationsCount":4},"100588663","reduction-of-complications-associated-with-picc-management-100588663","NCT06944327","Reduction of Complications Associated With PICC Management","Reduction of Complications Associated With PICC Management. Randomization in Care.","PICC managemen","Inclusion Criteria:\n\n* be over 18 years of age\n* accept participation in the study\n* independent patient in the care and management of activities of daily living\n\nExclusion Criteria:\n\n* patient over 18 years of age\n* patient with functional or cognitive limitation\n* patient with mild, moderate or high level of dependence\n* patient does not accept to perform the study\n* patient with device withdrawal prior to 14 days of duration",{"count":274,"type":20},460,[23],"The present study aims to analyze different care routes of the peripheral access central venous catheter to assess which alternative allows a moderate reduction in the level of complications associated with prolonged care frequency, due to the reduction of device manipulation.\n\nA high level of patient satisfaction is detected due to the controlled follow-up of the device care, as well as a decrease in the need for transfer to a center for follow-up.\n\nObjective: Identify the type of care frequency for PIVCs most beneficial for the reduction of complications associated with extraluminal device care (thrombosis, phlebitis, accidental removal, obstruction).",[278,28,279,29,280,281,282],"Treatment Outcome","Vascular Access Device","Care Delivery","Nurse","Nurse Based Care Management",[284,285,286,287,288,289,290,291],"vascular","vascular access","catheter","central catheter","nurse","vascular access device","management","complication",{"date":293,"type":38},"2025-04-25",{"date":214,"type":20},{"date":42,"type":20},{"name":297,"class":45},"Fundacion Miguel Servet",{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":11,"sex":16,"minAge":306,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":21,"phases":309,"briefSummary":310,"conditions":311,"keywords":316,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":46},"100588234","novel-medical-device-for-pharmacological-therapy-100588234","NCT06938750","Novel Medical Device for Pharmacological Therapy","A Pilot Study of a Novel Medical Device for Pharmacological Therapy: The SecHold Device","Sechold","Inclusion Criteria:\n\n* patients admitted to the intensive care unit\n* patients with authorization to take part in the study\n\nExclusion Criteria:\n\n* Patients with pre-existing medical conditions: Patients with diseases affecting coagulation, such as hemophilia or thrombocytopathies, could be excluded.\n* Active infection patients: Any patient with vascular access site infections or systemic infections may be excluded to avoid complications.\n* Inability to give informed consent: Patients who are unable to understand or consent to participate in the study.","1 Year",{"count":308,"type":20},262,[23],"Background: Different co-creation methods were used to design and prototype a new fixative device for multiple intravenous therapies with the ability to control and identify the pharmacological therapy administered to a patient. Objectives: To validate a newly created device for the reduction of complications related to the use of intravenous therapy Methods: A multidisciplinary team composed of eight professionals specializing in the field of critical care and an engineering professional in industrial design was responsible for collecting, evaluating, and materializing the ideas and needs arising from clinical practice in a device that met the standards of the same.",[28,29,312,313,61,314,281,282,315],"Vascular Access Complications","Catheter Malfunction","Therapeutic Drug Management","Innovative Procedures",[317,318,319,320,321,322],"VASCULAR ACCESS","CATHETER","THERAPY","COMPLICATION","DEVICE","CENTRAL VASCULAR ACCESS","2025-04-14",{"date":325,"type":38},"2025-04-22",{"date":327,"type":38},"2023-01-20",{"date":329,"type":20},"2026-09-20",{"name":297,"class":45},{"id":332,"slug":333,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":337,"eligibilityCriteria":338,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":339,"targetDuration":4,"studyType":21,"phases":341,"briefSummary":342,"conditions":343,"keywords":4,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":354},"100368472","radial-vs-state-of-the-art-femoral-access-for-bleeding-and-access-site-complication-reduction-in-cardiac-catheterization-rebirth-100368472","NCT04077762","Radial Vs. State-Of-The-Art Femoral Access for Bleeding and Access Site Complication Reduction in Cardiac Catheterization (REBIRTH)","Radial Vs. State-Of-The-Art Femoral Access for Bleeding and Access SIte Complication Reduction in Cardiac Catheterization (REBIRTH)","REBIRTH","Inclusion Criteria:\n\n* Age 18 years and older\n* Undergoing diagnostic angiography for ischemic symptoms with possible PCI, or undergoing planned urgent or elective PCI\n* Has provided informed consent and agrees to participate\n* Patients must be equally eligible to undergo cardiac catheterization via radial or femoral access\n\nExclusion Criteria:\n\n* Primary PCI for STEMI\n* Planned right heart catheterization\n* Valvular heart disease requiring valve surgery within 30 days after the index procedure\n* Hemodialysis access (arteriovenous fistula or graft) in the arm to be used for PCI in case of assignment to radial approach (the opposite arm may be used for radial access if a dialysis graft is present in one)\n* Peripheral arterial disease prohibiting vascular access\n* Presence of bilateral internal mammary artery coronary bypass grafts\n* International normalized ratio ≥1.5 while treated with oral vitamin K antagonists (i.e. warfarin) Receipt of oral factor Xa or IIa inhibitors ≤24 h before procedure\n* Planned staged PCI within 30 days after index procedure.\n* Any planned surgeries within 30 days after index procedure\n* Planned dual arterial access (for example for chronic total occlusion PCI)\n* Coexisting conditions that limit life expectancy to less than 30 days\n* Positive pregnancy test",{"count":340,"type":20},3266,[23],"This is a phase IV, prospective, open label, randomized-controlled study that will compare radial access with state-of-the-art femoral access in patients without ST-segment elevation acute myocardial infarction undergoing cardiac catheterization. Subjects will be randomized 1:1 into 2 treatment groups: radial access and state-of-the-art femoral access. Randomization will be performed in blocks of 50 per site. Similarly, a second sub-randomization will be performed in the femoral access group into use of 18 vs 21 gauge needles, also in a 1:1 fashion.",[344,29],"Patient Satisfaction","2025-01-22",{"date":347,"type":38},"2025-01-24",{"date":349,"type":38},"2019-11-15",{"date":351,"type":20},"2028-08-19",{"name":353,"class":45},"Minneapolis Heart Institute Foundation",6,{"id":356,"slug":357,"hasResults":11,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":21,"phases":364,"briefSummary":365,"conditions":366,"keywords":4,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":46},"100558389","comparison-of-three-types-of-distal-arteriovenous-fistulas-sbavf-rcavf-and-rcavf-with-venous-branch-patch-100558389","NCT06550479","Comparison of Three Types of Distal Arteriovenous Fistulas: SBAVF, RCAVF, and RCAVF With Venous Branch Patch.","Comparison of Tree Types of Distal Arteriovenous Fistulas: Snuffbox Fistula (SBAVF), Radiocephalic Fistula (RCAVF) and RCAVF With Venous Branch Patch.","Inclusion Criteria:\n\n* Aged \\>18 years\n* Chronic kidney disease with estimated glomerular filtration rate (eGFR) \\\u003C20 mL\u002Fmin\u002F1.73 m2\n\nExclusion Criteria:\n\n* Heart failure of New York Heart Association functional class III or IV,\n* Episode of cardio- or cerebrovascular event or receiving intervention therapy within 3 months prior to screening.\n* The patient had the primary anastomosis in the past on ipsilateral extremity",{"count":363,"type":20},180,[23],"This study aims to determine which type of distal arteriovenous fistula (SBAVF, RCAVF, and RCAVF with venous branch patch) is most clinically favorable.\n\nThe recommendations and scientific evidence do not suggest which option should be chosen initially.\n\nThe investigators expect that results will show which type of the anastomosis should be preferred.",[254,29],"2024-08-08",{"date":369,"type":38},"2024-08-13",{"date":371,"type":38},"2024-01-01",{"date":373,"type":20},"2030-07-31",{"name":375,"class":45},"Wroclaw Medical University"]